Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Tianjin Ringpu Bio-Technology Co.,Ltd. (300119.SZ)
Tianjin, CN
Established in 1998 and based in Tianjin, China, Tianjin Ringpu Bio-Technology Co.,Ltd. focuses on the research, development, manufacturing, and commercialization of a broad spectrum of animal health solutions. Their product portfolio includes veterinary biologicals, pharmaceutical formulations, functional feed additives, and active pharmaceutical ingredients (APIs) for the Chinese market. The company provides a wide array of vaccines and medications for livestock, particularly poultry and swine. They also offer a comprehensive line of pet care products, such as inactivated rabies vaccines, recombinant canine-alpha interferon, inhalation anesthetics like isoflurane and sevoflurane for dogs and cats, cefquinoxime sulfate injections for bacterial infections, and cardiac treatments including napril chewable tablets. For waterfowl, their specialized offerings include live and inactivated duck tempusu vaccines, purified egg yolk antibodies for gosling plague and duck viral hepatitis, duck infectious serositis inactivated vaccines, as well as injectable and soluble powder treatments like florfenicol and kanamycin. Furthermore, Ringpu develops antifungal products featuring natural plant extracts, immune polysaccharides, probiotics (such as Clostridium butyricum and Lactobacillus plantarum), antibacterial peptides, enzyme preparations, and acidulants. Their disinfection and cleaning range comprises potassium hydrogen persulfate composite powder, various quaternary ammonium compounds (e.g., benzyl trimethyl ammonium chloride, deca methyl ammonium bromide), sodium dichloroisocyanurate, and iodine glycerin solutions. The company's API production includes crucial ingredients like tilmicosin, tilmicosin phosphate, monbutone, tidiroxine, florfenicol, vonimulin hydrochloride, and gamimycin.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.09% | -1.94% | -10.33% | -18.03% | -18.69% | -14.01% | -34.34% | -16.02% | -57.58% | +7.53% | +5.98% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | -1 |
| Buy | 5 | -1 |
| Hold | 0 | 0 |
| Sell | 1 | +1 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+10.7% ★ Q1'26: +0.5% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+35.4% ★ Q1'26: -4.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+4.6% Q1'26: -4.6% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+14.9% ★ Q1'26: +16.5% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+10.1% ★ Q1'26: +9.5% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-1.3% ★ Q1'26: -0.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×1.59× ★ Q1'26: 3.07× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 4 EPS Ana. |
Dec 2027 6 Rev. Ana. 4 EPS Ana. |
Dec 2028 3 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
792.83M
est: 777.00M (+2.0%)
|
969.86M
est: 970.00M (0.0%)
|
1.05B
est: 986.00M (+6.2%)
|
1.19B
est: 1.21B (-1.9%)
|
1.47B
est: 1.44B (+2.1%)
|
2.00B
est: 1.99B (+0.3%)
|
2.15B
est.
|
2.01B
est: 2.07B (-3.1%)
|
2.08B
est: 2.35B (-11.5%)
|
2.71B
est: 2.35B (+15.1%)
|
3.07B
est: 2.62B (+17.2%)
|
3.40B
est: 3.64B (-6.6%)
|
3.83B
3.81B – 3.86B
+5.2% YoY
|
4.44B
4.16B – 4.68B
+16.0% YoY
|
5.35B
5.21B – 5.50B
+20.6% YoY
|
| EBITDA |
196.65M
est: 165.01M (+19.2%)
|
266.08M
est: 205.99M (+29.2%)
|
250.85M
est: 209.39M (+19.8%)
|
271.35M
est: 257.49M (+5.4%)
|
376.26M
est: 304.95M (+23.4%)
|
634.38M
est: 423.42M (+49.8%)
|
455.89M
est.
|
596.07M
est: 439.98M (+35.5%)
|
550.22M
est: 584.19M (-5.8%)
|
736.66M
est: 584.19M (+26.1%)
|
593.63M
est: 650.31M (-8.7%)
|
729.46M
est: 903.49M (-19.3%)
|
950.21M
946.47M – 957.39M
+5.2% YoY
|
1.10B
1.03B – 1.16B
+16.0% YoY
|
1.33B
1.29B – 1.37B
+20.6% YoY
|
| EBIT |
146.57M
est: 125.36M (+16.9%)
|
188.88M
est: 156.49M (+20.7%)
|
160.37M
est: 159.07M (+0.8%)
|
179.60M
est: 195.62M (-8.2%)
|
284.97M
est: 231.67M (+23.0%)
|
538.63M
est: 321.67M (+67.4%)
|
346.35M
est.
|
512.10M
est: 334.26M (+53.2%)
|
442.77M
est: 455.63M (-2.8%)
|
597.91M
est: 455.63M (+31.2%)
|
401.24M
est: 507.20M (-20.9%)
|
505.85M
est: 704.66M (-28.2%)
|
741.10M
738.19M – 746.70M
+5.2% YoY
|
859.49M
805.95M – 905.64M
+16.0% YoY
|
1.04B
1.01B – 1.06B
+20.6% YoY
|
| Net Income |
110.31M
est: 149.14M (-26.0%)
|
132.78M
est: 151.90M (-12.6%)
|
104.90M
est: 177.22M (-40.8%)
|
118.98M
est: 138.09M (-13.8%)
|
194.36M
est: 205.61M (-5.5%)
|
398.20M
est: 403.54M (-1.3%)
|
497.14M
est.
|
412.78M
est: 344.80M (+19.7%)
|
346.70M
est: 433.81M (-20.1%)
|
453.59M
est: 433.81M (+4.6%)
|
300.72M
est: 416.46M (-27.8%)
|
400.51M
est: 453.50M (-11.7%)
|
424.70M
412.28M – 467.87M
-6.4% YoY
|
538.63M
448.08M – 591.46M
+26.8% YoY
|
648.61M
453.92M – 799.09M
+20.4% YoY
|
| SGA |
325.37M
est: 183.72M (+77.1%)
|
374.09M
est: 229.36M (+63.1%)
|
319.49M
est: 233.14M (+37.0%)
|
341.68M
est: 286.69M (+19.2%)
|
420.80M
est: 339.54M (+23.9%)
|
521.48M
est: 471.44M (+10.6%)
|
507.60M
est.
|
529.17M
est: 489.89M (+8.0%)
|
486.89M
est: 482.49M (+0.9%)
|
584.43M
est: 482.49M (+21.1%)
|
640.33M
est: 537.09M (+19.2%)
|
351.11M
est: 746.20M (-52.9%)
|
784.78M
781.70M – 790.72M
+5.2% YoY
|
910.15M
853.46M – 959.02M
+16.0% YoY
|
1.10B
1.07B – 1.13B
+20.6% YoY
|
| EPS |
0.28
est: 0.32 (-13.6%)
|
0.34
est: 0.33 (+3.0%)
|
0.26
est: 0.39 (-32.5%)
|
0.29
est: 0.30 (-3.3%)
|
0.49
est: 0.45 (+9.7%)
|
1.01
est: 0.88 (+15.2%)
|
1.08
est.
|
1.03
est: 0.75 (+37.5%)
|
0.75
est: 0.94 (-20.2%)
|
0.98
est: 0.94 (+4.3%)
|
0.65
est: 0.92 (-29.2%)
|
0.88
est: 1.00 (-12.0%)
|
0.97
0.91 – 1.03
-3.1% YoY
|
1.19
0.99 – 1.30
+22.9% YoY
|
1.45
1.00 – 1.76
+21.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-28 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-27 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-26 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-25 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-22 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-21 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-20 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-19 | B+ | 3/5 | 3/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-18 | B+ | 3/5 | 3/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-15 | B+ | 3/5 | 3/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-14 | B+ | 3/5 | 3/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-13 | B+ | 3/5 | 3/5 | 4/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-12 | B+ | 3/5 | 3/5 | 4/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-11 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-08 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-07 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-06 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-30 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-29 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-21 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-20 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-17 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 46.6K | 0.46% |
| 2 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 138.2K | 0.39% |
| 3 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 110.6K | 0.29% |
| 4 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 68.5K | 0.28% |
| 5 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 2.5K | 0.44% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ailing Liu | Deputy GM & Director | — | female |
| Cai Xia Wang | Head of Accounting Department | — | — |
| Endong Bao | Chief Inspector of Technology Centre | — | male |
| Gaibian Li | Financial Manager | — | female |
| Gang Xie | Board Secretary | — | male |
| Lei Xu | GM & Director | — | male |
| Xiutong Zhu | Non-Independent Director & Deputy GM | — | male |
| Yongjun You | Deputy General Manager | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300119.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
